Tetrahedron 66 (2010) 8846-8853

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

An easy synthetic approach to 1,2,3-triazole-fused heterocycles

Vito Fiandanese*, Giuseppe Marchese, Angela Punzi, Francesco Iannone, Giacomo G. Rafaschieri

Dipartimento di Chimica, Università di Bari, via Orabona 4, 70126 Bari, Italy

ARTICLE INFO

ABSTRACT

functionalization of a C-H bond.

Article history: Received 30 June 2010 Received in revised form 1 September 2010 Accepted 20 September 2010 Available online 24 September 2010

Keywords: Cycloaddition Click chemistry Alkynes Azides Triazole-fused heterocycles

1. Introduction

Because of the widespread application of structurally novel heterocycles in drug development, nitrogen heterocycles, such as 1,2,3-triazoles, have received considerable attention due to their applications ranging from medicinal chemistry¹ to material science.² In addition, several heterocycles containing the 1,2,3-triazole ring system are reported to possess a broad spectrum of biological properties, such as antibacterial,³ antiallergic,⁴ and anti-HIV activity.⁵ The most popular method for the synthesis of 1,2,3-triazoles is the Huisgen 1,3-dipolar cycloaddition reaction of azides with alkynes.⁶ However, the original reactions were severely limited by the high reaction temperatures and the low regioselectivity. These limitations have been overcome by the introduction of the copper catalyzed 1,3-dipolar cycloaddition of terminal alkynes and azides, so-called 'click chemistry'.^{7,8} The cycloaddition reactions of terminal alkynes with azides catalyzed by Cu(I) can be conducted at room temperature and are highly regioselective leading exclusively to 4-substituted-1,2,3-triazoles. The number of publications dealing with click chemistry has grown exponentially over the last few years,^{9,10} and, in particular, this methodology has been widely used by many research groups for the synthesis of several bicyclic, as well as polycyclic fused triazoles heterocycles,¹¹ compounds of great interest for their various biological and pharmacological activities.^{11,12} Mainly, fused triazoles are prepared by an intramolecular 1,3-dipolar cycloaddition between azides and alkynes^{11b,i} and a one-pot copper-^{11c} or palladium-catalyzed ^{11d,e,l} coupling reaction followed by a [3+2] cycloaddition. An alternative approach may involve an intramolecular direct transition metal-catalyzed arylation of 1,2,3triazoles by cleavage of C–H bonds with aryl halides, ^{11g,h} a methodology which has been recently shown to be a powerful synthetic tool for functionalization of heterocycles.¹³

A convenient synthesis of 1.2.3-triazole-fused isoindolines and dihydroisoguinolines in good to excellent

yield is reported, starting from easily available terminal alkynes and (2-haloaryl)alkylazides. The method

is based upon a cycloaddition reaction, via click chemistry, followed by a transition metal-catalyzed

Owing to our continuing interest in the synthesis of novel structures of biological significance,^{14–16} we recently reported a straightforward synthesis of a variety of heterocyclic compounds, with an indole and benzofuran skeleton,^{14a,b} and an easy and general approach¹⁵ to more complex 4-substituted-1,2,3-triazoles,^{15a} and to unsymmetrically substituted 4,4'-bi-1,2,3-triazoles,^{15b} via click chemistry. During our studies, we became interested in developing an easy approach to 1,2,3-triazole-fused heterocycles. Herein we wish to report on these studies, which enabled the synthesis of the title compounds through a reaction sequence involving a pre-liminary cycloaddition of easily available terminal alkynes and (2-haloaryl)alkylazides, followed by an intramolecular direct transition metal-catalyzed C–H arylation.

2. Results and discussion

Our strategy is depicted in Scheme 1. We started with the cycloaddition reaction between (2-haloaryl)alkylazides, 2-iodo- or 2-bromobenzylazide (**1**, n=0) and 2-(2-iodophenyl)ethylazide or 2-(2-bromophenyl)ethylazide (**2**, n=1) and several terminal alkynes **3**. All reactions were performed in H₂O at 100 °C in the presence of Cu(OAc)₂·H₂O as a catalyst^{15b} (20 mol %), leading to functionalized 1,4-substituted-1,2,3-triazoles **4** (n=0) and **5** (n=1).






© 2010 Elsevier Ltd. All rights reserved.

^{*} Corresponding author. Tel./fax: +39 080 5442075; e-mail address: fianda@ chimica.uniba.it (V. Fiandanese).

^{0040-4020/\$ —} see front matter @ 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2010.09.068



Scheme 1.

To obtain the annulated triazoles 6 and 7 we investigated the catalytic activity of various Pd catalyst and we found¹⁷ that compounds 4 and 5 were easily cyclized in the presence of PdCl₂(PPh₃)₂ (5 mol %), leading respectively to 1,2,3-triazole-fused isoindolines **6** (n=0) and dihydroiso-quinolines **7** (n=1). It is noteworthy that, relatively to compounds 6, there is only one report regarding the synthesis of triazole-fused isoindolines, obtained in fair yields employing the 2-iodobenzylazide and various terminal alkynes, in a one-pot Pd-catalyzed coupling reaction and cycloaddition.¹¹¹ Our procedure is completely different and, as reported in Table 1, the novel compounds 4 and the 1,2,3triazole-fused isoindolines 6 were obtained in high yields. Moreover, the reactions can be performed both with 2-iodobenzylazide 1a (entries 1, 4, and 6) and 2-bromobenzylazide 1b (entries 2, 3, 5, and 7), and alkyl- (entries 1-3), aryl- (entries 4-6) and heteroaryl-acetylenes (entry 7) were used. With the same strategy we were able to perform the synthesis of functionalized 1,2,3-triazole-fused 5,6-dihydroisoquinolines,^{11g} simply by employment of 2-(2-iodophenvl)ethylazide 2a and

2-(2-bromophenyl)ethyl azide **2b**. We wish to emphasize that the isoquinoline derivatives are an important class of alkaloids and many biologically active natural products contain the isoquinoline framework¹⁸ and their biological activities have made them useful in pharmaceutical compounds.¹⁹ The overall results are reported in Table 2. Also in this case we can use azide **2a** (entries 1, 2, 4, 5, and 7) or azide **2b** (entries 3 and 6) obtaining the novel intermediates **5** in high yields, substituted in position 4 by alkyl-(entries 1–3), or aryl- (entries 4–6), or 3-thienyl-group (entry 7). The intramolecular direct Pd-catalyzed C–H arylation of novel compounds **5** led to 1,2,3-triazole-fused 5,6-dihydroisoquinolines **7** in high yields.

In summary, the procedure described here appears to be a useful route to 1,2,3-triazole-fused heterocycles **6** and **7** and compares favorably with other methodologies. We have shown that the title compounds can be easily synthesized by simple cycloaddition reactions, via click chemistry, followed by an intramolecular direct transition metal-catalyzed C–H arylation.

3. Experimental

3.1. General

Macherey–Nagel silica gel (60, particle size 0.040–0.063 mm) for column chromatography and Macherey–Nagel aluminum sheets with silica gel 60 F_{254} for TLC were used. GC analysis was performed on a Varian 3900 gas chromatograph equipped with a Supelco SLBTM-5ms capillary column (30 m×0.25 mm id). GC/ mass-spectrometry analysis was performed on a Shimadzu GCMS-QP5000 gas chromatograph-mass spectrometer equipped with a Supelco SLBTM-5ms capillary column (30 m×0.25 mm id). ¹H NMR spectra were recorded in deuterochloroform, CD₂Cl₂ or acetone-*d*₆ on a Varian Inova at 400 MHz. ¹³C NMR spectra were recorded in deuterochloroform, CD₂Cl₂ or acetone-*d*₆ on a Varian Inova at 100.6 MHz. IR spectra were recorded on a Perkin–Elmer FT-IR Spectrum Bx. Elemental analyses were recorded on a Carlo Erba EA 1108 elemental analyzer. Melting points were determined on a Reichert Microscope. NMP was used as supplied.

3.2. General procedure for the synthesis of compounds 4 and 5

Alkyne **3** (1.2 equiv) and azide (1 equiv) were added at room temperature to a solution (0.04 M) of Cu(OAc)₂·H₂O (0.2 equiv) in H₂O in a capped flask. The mixture was stirred at 100 °C and, after reaction completion (1–4 h), was quenched with a saturated aqueous solution of NH₄Cl (20 mL) and extracted with ethyl acetate (3×30 mL). The organic extracts were washed with an aqueous solution of NaCl (3×20 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by column chromatography on silica gel and by crystallization.

3.2.1. 1-(2-Iodobenzyl)-4-octyl-1H-1,2,3-triazole (4a). Compound 4a was prepared from 2-iodobenzylazide (0.400 g, 1.54 mmol) and 1-decyne (0.256 g, 1.85 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.446 g of compound 4a (73% vield). After crystallization from ethyl acetate/petroleum ether, compound 4a was obtained as a white solid, mp=96-98 °C. [Found: C, 47.42; H, 5.13; N, 11.90. C₁₄H₁₈IN₃ requires C, 47.34; H, 5.11; N, 11.83%.] ν_{max} (KBr) 3108, 3057, 2949, 2919, 2849, 1463, 1458, 1436, 1219, 1054, 1012, 750, 742; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.88–7.84 (m, 1H), 7.30 (td, *J*=7.6, 1.2 Hz, 1H), 7.26 (s, 1H), 7.04-6.98 (m, 2H), 5.55 (s, 2H), 2.68 (t, J=7.6 Hz, 2H), 1.62 (quintet, J=7.6 Hz, 2H), 1.36–1.17 (m, 10H), 0.84 (t, J=7.0 Hz, 3H); δ_{C} (100.6 MHz, CDCl₃) 148.9, 139.7, 137.6, 130.2, 129.4, 129.0, 120.9, 98.4, 58.2, 31.8, 29.4, 29.3, 29.2, 29.2, 25.7, 22.6, 14.1; MS m/z 397 (M⁺, 3), 299 (7), 270 (5), 217 (100), 186 (5), 152 (6), 90 (34), 69 (7), 55 (11), 43 (9), 41 (18%).

3.2.2. 1-(2-Bromobenzyl)-4-cyclohexyl-1H-1,2,3-triazole (4b). Compound 4b was prepared from 2-bromobenzylazide (0.199 g, 0.94 mmol) and cyclohexylacetylene (0.122 g, 1.13 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by percolation (florisil, 50% ethyl acetate/petroleum ether) afforded 0.283 g of compound 4b (94% yield). After crystallization from ethyl acetate/petroleum ether, compound 4b was obtained as a white solid, mp=120-121 °C. [Found: C, 56.35; H, 5.70; N, 13.15. C₁₅H₁₈BrN₃ requires C, 56.26; H, 5.67; N, 13.12%.] v_{max} (KBr) 3109, 3057, 2919, 2849, 1448, 1209, 1044, 1026, 759, 744; δ_H (400 MHz, CDCl₃) 7.58 (dd, *J*=7.6, 1.2 Hz, 1H), 7.30–7.24 (m, 2H), 7.18 (td, J=7.6, 1.6 Hz, 1H), 7.05 (dd, J=7.6, 1.6 Hz, 1H), 5.59 (s, 2H), 2.77-2.68 (m, 1H), 2.06-1.98 (m, 2H), 1.80-1.64 (m, 3H), 1.42-1.14 (m, 5H); δ_C (100.6 MHz, CDCl₃) 154.1, 134.6, 133.0, 130.1, 130.0, 128.1, 123.2, 119.5, 53.5, 35.3, 32.9, 26.1, 26.0; MS m/z 321 (M+2, 3), 319 (M⁺, 3), 265 (4), 263 (4), 184 (7), 171 (79), 169 (100), 122 (31), 95 (14), 90 (46), 89 (36), 80 (18), 67 (21), 63 (13), 55 (16), 53 (14), 51 (12%).

3.2.3. 1-(2-Bromobenzyl)-4-(cyclopentylmethyl)-1H-1,2,3-triazole (**4c**). Compound **4c** was prepared from 2-bromobenzylazide (0.199 g, 0.94 mmol) and 3-cyclopentyl-1-propyne (0.123 g, 1.13 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.283 g of compound **4c** (94% yield). After crystallization from petroleum ether, compound **4c** was obtained as a white solid, mp=62–63 °C.

Table 1

Synthesis of	123_triazoles 4 and	1,2,3-triazole-fused isoindolines 6
Synthesis of	1,2,5 thazoics + and	1,2,5-11102010-10300 13011100111103 0

Entry	Azides 1	Alkynes 3	Products 4 ^a , yield ^b (%)	Products 6 ^c , yield ^b (%)
1	N ₃	1-Decyne	N-N C ₈ H ₁₇	NNN H ₁₇ C ₈
2	1a N ₃ Br 1b	Cyclohexylacetylene	4a (73)	6a (77)
3	16	3-Cyclopentyl-1-propyne	4b (94) Br 4c (94)	60 (83)
4	1a	Phenylacetylene	4d (77)	N-N N 6d (68)
5	16	p-Tolylacetylene		
6	1a	<i>p</i> -Methoxyphenylacetylene	4e (95)	6e (87)
7	16	3-Ethynyltiophene	4g (96)	6g (95)

 $^a\,$ All reactions were carried out in H_2O in a capped flask at 100 $^\circ\text{C}$, according to a general procedure.

^b Yields of purified isolated products.

^c All reactions were carried out in NMP at 100 °C, according to a general procedure.

[Found: C, 56.30; H, 5.73; N, 13.20. $C_{15}H_{18}BrN_3$ requires C, 56.26; H, 5.67; N, 13.12%.] ν_{max} (KBr) 3115, 3063, 2936, 2862, 1439, 1212, 1141, 1046, 1031, 751, 739; δ_{H} (400 MHz, CDCl₃) 7.58 (dd, *J*=7.6, 1.2 Hz, 1H), 7.30–7.23 (m, 2H), 7.18 (td, *J*=7.6, 1.6 Hz, 1H), 7.04 (dd, *J*=7.6, 1.6 Hz, 1H), 5.59 (s, 2H), 2.68 (d, *J*=7.6 Hz, 2H), 2.14 (septet, *J*=7.6 Hz, 1H), 1.76–1.65 (m, 2H), 1.64–1.42 (m, 4H), 1.25–1.10 (m, 2H); δ_{C} (100.6 MHz, CDCl₃) 148.3, 134.6, 133.1, 130.1, 129.9, 128.1, 123.2, 121.2, 53.5, 39.9, 32.4, 31.7, 25.1; MS *m*/*z* 253 (8), 251 (8), 171 (79),

169 (100), 144 (11), 122 (13), 95 (15), 90 (39), 89 (31), 80 (11), 79 (11), 67 (14), 54 (11), 41 (61%).

3.2.4. 1-(2-lodobenzyl)-4-phenyl-1H-1,2,3-triazole (**4d**). Compound **4d** was prepared from 2-iodobenzylazide (0.300 g, 1.16 mmol) and phenylacetylene (0.142 g, 1.39 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/

 Table 2

 Synthesis of 1,2,3-triazoles 5 and 1,2,3-triazole-fused 5,6-dihydroisoquinolines 7

Entry	Azides 2	Alkynes 3	Product 5 ^a , yield ^b (%)	Product 7 ^c , yield ^b (%)
1	2a	1-Heptyne	H ₁₁ C ₅ 5a (86)	H ₁₁ C ₅ 7a (94)
2	2a	1-Decyne	$ \begin{array}{c} $	$H_{17}C_8^{N}$
3	Br 2b	Cyclohexylacetylene	5c (71)	7c (87)
4	2a	Phenylacetylene		N N N N N N N N N N N N N N N N N N N
5	2a	p-Tolylacetylene	5d (97)	7d (82)
6	2b	<i>p</i> -Methoxyphenylacetylene	Br N N MeO	MeO 7f (74)
7	2a	3-Ethynylthiophene	5f (99)	7g (87)

 $^a\,$ All reactions were carried out in H_2O in a capped flask at 100 $^\circ C$, according to a general procedure.

^b Yields of purified isolated products.

^c All reactions were carried out in NMP at 100 °C, according to a general procedure.

petroleum ether) afforded 0.322 g of compound **4d** (77% yield). After crystallization from ethyl acetate/petroleum ether, compound **4d** was obtained as a pale yellow solid, mp=115–117 °C. [Found: C, 49.95; H, 3.38; N, 11.70. C₁₅H₁₂IN₃ requires C, 49.88; H, 3.35; N, 11.63%.] v_{max} (KBr) 3112, 3076, 3028, 1459, 1437, 1419, 1228, 1090,

1051, 1015, 764, 742, 694; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.89 (dd, *J*=7.6, 1.2 Hz, 1H), 7.83–7.78 (m, 2H), 7.75 (s, 1H), 7.42–7.37 (m, 2H), 7.36–7.28 (m, 2H), 7.12 (dd, *J*=7.6, 1.6 Hz, 1H), 7.04 (td, *J*=7.6, 1.6 Hz, 1H), 5.65 (s, 2H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 148.1, 139.9, 137.3, 130.4, 130.4, 129.6, 129.1, 128.8, 128.2, 125.7, 119.8, 98.6, 58.4; MS *m/z* 361

(M⁺, 6), 332 (4), 217 (36), 206 (53), 178 (6), 128 (10), 116 (100), 102 (35), 90 (54), 89 (62), 77 (13), 63 (24), 51 (17%).

3.2.5. 1-(2-Bromobenzyl)-4-(4-methylphenyl)-1H-1,2,3-triazole (4e). Compound 4e was prepared from 2-bromobenzylazide (0.199 g, 0.94 mmol) and 4-ethynyltoluene (0.131 g, 1.13 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0. 293 g of compound 4e (95% yield). After crystallization from ethyl acetate/petroleum ether, compound 4e was obtained as a white solid, mp=133-134 °C. [Found: C, 58.50; H, 4.28; N, 12.75. C₁₆H₁₄BrN₃ requires C, 58.55; H, 4.30; N, 12.80%.] *v*_{max} (KBr) 3126, 3105, 2925, 1458, 1442, 1427, 1350, 1222, 1046, 1026, 820, 748; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.72 (s, 1H), 7.71–7.67 (m, 2H), 7.60 (dd, *J*=7.6, 1.2 Hz, 1H), 7.29 (td, *J*=7.6, 1.2 Hz, 1H), 7.23–7.18 (m, 3H), 7.17–7.13 (m, 1H), 5.67 (s, 2H), 2.35 (s, 3H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 148.2, 138.0, 134.3, 133.1, 130.3, 130.2, 129.5, 128.2, 127.6, 125.6, 123.3, 119.4, 53.8, 21.2; MS m/z 329 (M+2, 3), 327 (M⁺, 3), 300 (3), 298 (3), 220 (31), 171 (18), 169 (22), 130 (100), 110 (10), 103 (19), 90 (22), 89 (21), 77 (21), 63 (11), 51 (13%).

3.2.6. 1-(2-Iodobenzyl)-4-(4-methoxyphenyl)-1H-1,2,3-triazole (4f). Compound 4f was prepared from 2-iodobenzylazide (0.300 g, 1.16 mmol) and p-methoxyphenylacetylene (0.184 g, 1.39 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.408 g of compound 4f (90% yield). After crystallization from ethyl acetate/petroleum ether, compound **4f** was obtained as a pale vellow solid. mp=140-141 °C. [Found: C, 49.08; H, 3.58; N, 10.75. C₁₆H₁₄IN₃O requires C, 49.12; H, 3.61; N, 10.74%.] v_{max} (KBr) 3125, 3102, 2925, 1498, 1458, 1438, 1246, 1222, 1174, 1028, 1012, 830, 750; $\delta_{\rm H}$ (400 MHz, CDCl3) 7.88 (dd, *J*=7.7, 1.2 Hz, 1H), 7.75–7.70 (m, 2H), 7.67 (s, 1H), 7.31 (td, *J*=7.7, 1.2 Hz, 1H), 7.09 (dd, J=7.7, 1.6 Hz, 1H), 7.03 (td, J=7.7, 1.6 Hz, 1H), 6.94-6.89 (m, 2H), 5.62 (s, 2H), 3.81 (s, 3H); δ_{C} (100.6 MHz, CDCl3) 159.6, 148.0, 139.8, 137.4, 130.3, 129.5, 129.0, 127.0, 123.1, 119.0, 114.2, 98.5, 58.4, 55.3; MS *m*/*z* 391 (M+, 18), 236 (74), 221 (18), 217 (21), 193 (19), 165 (12), 146 (100), 128 (9), 119 (34), 103 (21), 90 (64), 89 (62), 76 (30), 65 (21), 63 (30), 51 (26), 50 (25%).

3.2.7. 1-(2-Bromobenzyl)-4-(thiophen-3-yl)-1H-1,2,3-triazole (4g). Compound 4g was prepared from 2-bromobenzylazide (0.199 g, 0.94 mmol) and 3-ethynylthiophene (0.122 g, 1.13 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.289 g of compound 4g (96% yield). After crystallization from ethyl acetate/petroleum ether, compound **4g** was obtained as an ivory-white solid, mp=99-100 °C. [Found: C, 48.91; H, 3.22; N, 13.15; S, 10.05. C₁₃H₁₀BrN₃S requires C, 48.76; H, 3.15; N, 13.12; S, 10.01%.] v_{max} (KBr) 3123, 3094, 2923, 1436, 1216, 1044, 1029, 850, 824, 784, 739, 711, 615; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.66 (s, 1H), 7.65 (dd, *J*=3.0, 1.2 Hz, 1H), 7.61 (dd, J=7.6, 1.2 Hz, 1H), 7.41 (dd, J=5.0, 1.2 Hz, 1H), 7.34 (dd, J=5.0, 3.0 Hz, 1H), 7.28 (td, J=7.6, 1.2 Hz, 1H), 7.21 (td, J=7.6, 2.0 Hz, 1H), 7.14 (dd, J=7.6, 2.0 Hz, 1H), 5.67 (s, 2H); δ_{C} (100.6 MHz, CDCl₃) 144.3, 134.2, 133.1, 131.6, 130.3, 130.1, 128.2, 126.3, 125.7, 123.3, 121.1, 119.6, 53.7; MS *m*/*z* 321 (M+2, 4), 319 (M⁺, 4), 292 (3), 290 (3), 212 (44), 184 (6), 171 (21), 169 (24), 122 (100), 106 (14), 95 (16), 90 (36), 89 (29), 63 (16), 51 (13), 45 (79%).

3.2.8. 1-[2-(2-Iodophenyl)ethyl]-4-pentyl-1H-1,2,3-triazole (**5a**). Compound **5a** was prepared from 2-iodophenylethylazide (0.150 g, 0.55 mmol) and 1-heptyne (0.064 g, 0.66 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.175 g of compound **5a**

(86% yield) as a pale yellow oil. [Found: C, 48.70; H, 5.51; N, 11.49. C₁₅H₂₀IN₃ requires C, 48.79; H, 5.46; N, 11.38%.] ν_{max} (neat) 3131, 3063, 2953, 2927, 2856, 1466, 1459, 1436, 1217, 1048, 1013, 750; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.80 (dd, *J*=7.7, 1.2 Hz, 1H), 7.17 (dd, *J*=7.7, 1.2 Hz, 1H), 7.00 (s, 1H), 6.95 (dd, *J*=7.7, 1.6 Hz, 1H), 6.89 (dd, *J*=7.7, 1.6 Hz, 1H), 4.50 (t, *J*=7.4 Hz, 2H), 3.27 (t, *J*=7.4 Hz, 2H), 2.62 (t, *J*=7.6 Hz, 2H), 1.57 (quintet, *J*=7.6 Hz, 2H), 1.35–1.18 (m, 4H), 0.84 (t, *J*=7.0 Hz, 3H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 148.1, 139.6, 139.6, 130.2, 128.9, 128.6, 120.9, 100.1, 49.5, 41.5, 31.2, 29.1, 25.5, 22.3, 13.9; MS *m/z* 242 (100), 231 (42), 217 (9), 170 (4), 158 (5), 124 (17), 117 (9), 104 (98), 95 (20), 90 (21), 77 (35), 68 (23), 55 (39), 41 (86%).

3.2.9. 1-[2-(2-Iodophenyl)ethyl]-4-octyl-1H-1,2,3-triazole (5b). Compound **5b** was prepared from 2-iodophenylethylazide (0.300 g, 1.10 mmol) and 1-decyne (0.183 g, 1.32 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.380 g of compound 5b (84% yield). After crystallization from petroleum ether, compound 5b was obtained as a white solid, mp=49-51 °C. [Found: C, 50.72; H, 5.88; N, 10.70. C₁₈H_{2.6}IN₃ requires C, 50.78; H, 5.94; N, 10.77%.] *v*_{max} (KBr) 3125, 3060, 2923, 2848, 1466, 1454, 1438, 1208, 1054, 1014, 752; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.81 (dd, *J*=7.6, 1.2 Hz, 1H), 7.18 (td, *J*=7.6, 1.2 Hz, 1H), 7.01 (s, 1H), 6.96 (dd, J=7.6, 1.6 Hz, 1H), 6.91 (td, J=7.6, 1.6 Hz, 1H), 4.52 (t, J=7.2 Hz, 2H), 3.28 (t, J=7.2 Hz, 2H), 2.63 (t, J=7.6 Hz, 2H), 1.57 (quintet, *J*=7.6 Hz, 2H), 1.32–1.17 (m, 10H), 0.85 (t, *J*=7.0 Hz, 3H); δ_C (100.6 MHz, CDCl₃) 148.2, 139.7, 139.7, 130.3, 128.9, 128.6, 121.0, 100.1, 49.5, 41.6, 31.8, 29.5, 29.3, 29.2, 29.1, 25.5, 22.6, 14.1; MS m/z 313 (4), 284 (100), 231 (60), 217 (11), 166 (10), 110 (32), 104 (98), 103 (23), 96 (20), 82 (15), 77 (26), 68 (21), 67 (17), 55 (30), 41 (77%).

3.2.10. 1-[2-(2-Bromophenyl)ethyl]-4-cyclohexyl-1H-1,2,3-triazole (5c). Compound 5c was prepared from 2-bromophenylethylazide (0.149 g, 0.66 mmol) and cyclohexylacetylene (0.086 g, 0.79 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.157 g of compound 5c (71% yield). After crystallization from ethyl acetate/petroleum ether, compound **5c** was obtained as a white solid, mp=81-82 °C. [Found: C, 57.53; H, 6.10; N, 12.65. C₁₆H₂₀BrN₃ requires C, 57.49; H, 6.03; N, 12.57%.] *v*_{max} (KBr) 3109, 3062, 2917, 2849, 1460, 1447, 1434, 1215, 1058, 1039, 1024, 752; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.53 (dd, *J*=7.6, 1.2 Hz, 1H), 7.16 (td, J=7.6, 1.2 Hz, 1H), 7.08 (td, J=7.6, 1.6 Hz, 1H), 6.98–6.92 (m, 2H), 4.54 (t, J=7.2 Hz, 2H), 3.29 (t, J=7.2 Hz, 2H), 2.74–2.65 (m, 1H), 2.00–1.90 (m, 2H), 1.79–1.62 (m, 3H), 1.43–1.13 (m, 5H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 153.5, 136.5, 133.0, 131.2, 128.8, 127.7, 124.2, 119.7, 49.3, 37.3, 35.2, 33.0, 26.1, 26.0; MS m/z 254 (78), 226 (8), 185 (29), 183 (30), 169 (9), 136 (63), 109 (33), 104 (73), 91 (25), 80 (38), 79 (38), 77 (56), 67 (64), 55 (29), 41 (100%).

3.2.11. 1-[2-(2-Iodophenyl)ethyl]-4-phenyl-1H-1,2,3-triazole (5d). Compound 5d was prepared from 2-iodophenylethylazide (0.150 g, 0.55 mmol) and phenylacetylene (0.067 g, 0.66 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.200 g of compound 5d (97% yield). After crystallization from ethyl acetate/petroleum ether, compound **5d** was obtained as a white solid, mp=115-117 °C. [Found: C, 51.19; H, 3.80; N, 11.25. C₁₆H₁₄IN₃ requires C, 51.22; H, 3.76; N, 11.20%.] v_{max} (KBr) 3116, 3089, 3055, 2958, 2930, 1466, 1436, 1221, 1076, 1015, 767, 751, 694; δ_H (400 MHz, CDCl₃) 7.85 (dd, J=7.6, 1.2 Hz, 1H), 7.78–7.73 (m, 2H), 7.51 (s, 1H), 7.42–7.36 (m, 2H), 7.33–7.28 (m, 1H), 7.21 (td, J=7.6, 1.2 Hz, 1H), 7.03 (dd, J=7.6, 1.8 Hz, 1H), 6.94 (td, J=7.6, 1.8 Hz, 1H), 4.62 (t, J=7.2 Hz, 2H), 3.37 (t, J=7.2 Hz, 2H); δ_{C} (100.6 MHz, CDCl₃) 147.3, 139.6, 139.3, 130.4, 130.1, 128.9, 128.6, 128.5, 127.9, 125.5, 119.9, 100.1, 49.7, 41.3; MS m/z 375 (M⁺, 2), 248 (41), 231 (19), 220 (13), 142 (5), 130 (25), 117 (28), 104 (100), 89 (32), 77 (51), 63 (22), 51 (31%).

3.2.12. 1-[2-(2-Iodophenyl)ethyl]-4-(4-methylphenyl)-1H-1,2,3-triazole (5e). Compound 5e was prepared from 2-iodophenylethylazide (0.200 g, 0.73 mmol) and 4-ethynyltoluene (0.102 g, 0.88 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.239 g of compound 5e (84% yield). After crystallization from ethyl acetate/petroleum ether, compound **5e** was obtained as a pale yellow solid, mp=118-120 °C. [Found: C, 52.53; H, 4.17; N, 10.85. C₁₇H₁₆IN₃ requires C, 52.46; H, 4.14; N, 10.80%.] v_{max} (KBr) 3082, 3057, 2942, 1459, 1436, 1219, 1188, 1086, 1047, 1014, 814, 761, 744, 530; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.83 (dd, J=7.6, 1.2 Hz, 1H), 7.67-7.62 (m, 2H), 7.48 (s, 1H), 7.23-7.16 (m, 3H), 7.02 (dd, *I*=7.6, 1.6 Hz, 1H), 6.92 (td, *I*=7.6, 1.6 Hz, 1H), 4.60 (t, *I*=7.4 Hz, 2H), 3.35 $(t, J=7.4 \text{ Hz}, 2\text{H}), 2.35 (s, 3\text{H}); \delta_{C}(100.6 \text{ MHz}, \text{CDCl}_{3}) 147.6, 139.7, 139.5,$ 137.9, 130.3, 129.4, 129.0, 128.7, 127.7, 125.5, 119.6, 100.1, 49.8, 41.5, 21.2; MS m/z 389 (M⁺, 7), 262 (23), 234 (29), 231 (29), 144 (39), 130 (18), 117 (54), 115 (64), 104 (100), 91 (27), 90 (25), 89 (22), 77 (46), 65 (13), 63 (17), 51 (25%).

3.2.13. 1-[2-(2-Bromophenyl)ethyl]-4-(4-methoxyphenyl)-1H-1,2,3triazole (5f). Compound 5f was prepared from 2-bromophenylethylazide (0.149 g, 0.66 mmol) and 4-ethynylanisole (0.104 g, 0.79 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.234 g of compound **5f** (99% vield). After crystallization from ethyl acetate/ petroleum ether, compound 5f was obtained as a white solid, mp=114-115 °C. [Found: C, 57.05; H, 4.45; N, 11.70. C₁₇H₁₆BrN₃O requires C, 57.00; H, 4.50; N, 11.73%.] v_{max} (KBr) 3088, 3044, 2952, 2932, 2834, 1502, 1472, 1443, 1435, 1248, 1081, 1026, 827, 758; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.69–7.65 (m, 2H), 7.56 (dd, J=7.6, 1.2 Hz, 1H), 7.41 (s, 1H), 7.16 (td, J=7.6, 1.2 Hz, 1H), 7.09 (td, J=7.6, 1.8 Hz, 1H), 7.02 (dd, J=7.6, 1.8 Hz, 1H), 6.94–6.89 (m, 2H), 4.62 (t, J=7.2 Hz, 2H), 3.80 (s, 3H), 3.35 (t, J=7.2 Hz, 2H); δ_{C} (100.6 MHz, CDCl₃) 159.5, 147.4, 136.3, 133.0, 131.2, 128.9, 127.8, 126.9, 124.3, 123.3, 119.1, 114.2, 55.3, 49.6, 37.2; MS *m*/*z* 359 (M+2, 12), 357 (M⁺, 13), 250 (32), 183 (15), 160 (74), 146 (29), 145 (27), 133 (100), 117 (60), 104 (82), 90 (40), 89 (68), 78 (22), 77 (80), 76 (23), 63 (36), 51 (40), 50 (24%).

3.2.14. 1-[2-(2-Bromophenyl)ethyl]-4-(thiophen-3-yl)-1H-1,2,3-triazole (5g). Compound 5g was prepared from 2-iodophenylethylazide (0.200 g, 0.73 mmol) and 3-ethynylthiophene (0.095 g, 0.88 mmol) and the reaction was performed at 100 °C in accordance with general procedure. Purification by column chromatography (silica gel, 30% ethyl acetate/petroleum ether) afforded 0.270 g of compound 5g (97% yield). After crystallization from ethyl acetate/ petroleum ether, compound 5g was obtained as a white solid, mp=92-94 °C. [Found: C, 50.35; H, 3.60; N, 12.62; S, 9.63. C₁₄H₁₂BrN₃S requires C, 50.31; H, 3.62; N, 12.57; S, 9.59%.] v_{max} (KBr) 3099, 3077, 2954, 2930, 1438, 1217, 1074, 1017, 853, 788, 754, 717, 624; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.83 (dd, *J*=7.6, 1.2 Hz, 1H), 7.61 (dd, *J*=2.8, 1.2 Hz, 1H), 7.42 (s, 1H), 7.38 (dd, J=5.0, 1.2 Hz, 1H), 7.34 (dd, J=5.0, 2.8 Hz, 1H), 7.21 (td, *J*=7.6, 1.2 Hz, 1H), 7.02 (dd, *J*=7.6, 1.6 Hz, 1H), 6.93 $(td, J=7.6, 1.6 Hz, 1H), 4.60 (t, J=7.4 Hz, 2H), 3.35 (t, J=7.4 Hz, 2H); \delta_C$ (100.6 MHz, CDCl₃) 143.7, 139.7, 139.5, 131.8, 130.3, 129.1, 128.7, 126.2, 125.8, 121.0, 119.7, 100.1, 49.8, 41.5; MS m/z 381 (M⁺, 8), 254 (35), 231 (16), 226 (17), 217 (7), 142 (15), 136 (56), 122 (23), 109 (67), 104 (100), 90 (32), 77 (53), 65 (24), 63 (25), 51 (33), 45 (90%).

3.3. General procedure for the synthesis of compounds 6 and 7

To a solution (0.1 N) of triazole (1 equiv) in NMP at room temperature under nitrogen were successively added PdCl₂(PPh₃)₂ (0.05 equiv) and *n*-Bu₄NOAc (2 equiv). The resulting mixture was stirred at 100 °C and, after reaction completion (1–5 h), was quenched with aqueous NH₄Cl (20 mL) and extracted with ethyl acetate (3×30 mL). The organic extracts were washed with an aqueous solution of NaCl (3×20 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum. The residue was purified by column chromatography on silica gel and by crystallization.

3.3.1. 3-Octyl-8H-[1,2,3]triazolo[5,1-a]isoindole (6a). Compound 6a was prepared from 4a (0.151 g, 0.38 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.079 g of compound **6a** (77% yield). After crystallization from petroleum ether, compound **6a** was obtained as a pale yellow solid, mp=79-80 °C. [Found: C, 75.87; H, 8.55; N, 15.70. C₁₇H₂₃N₃ requires C, 75.80; H, 8.61; N, 15.60%.] v_{max} (KBr) 2947, 2914, 2850, 1474, 1458, 1437, 1310, 1166, 765, 726; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.58 (br d, J=7.6 Hz, 1H), 7.49-7.41 (m, 2H), 7.35 (td, J=7.6, 1.2 Hz, 1H), 5.27 (s, 2H), 2.92 (t, J=7.6 Hz, 2H), 1.78 (quintet, J=7.6 Hz, 2H), 1.44–1.17 (m, 10H), 0.84 (t, *J*=6.8 Hz, 3H); δ_C (100.6 MHz, CDCl₃) 140.6, 139.3, 139.3, 128.7, 128.5, 127.6, 124.1, 120.8, 50.9, 31.8, 29.5, 29.3, 29.2, 29.2, 25.9, 22.6, 14.1; MS *m*/*z* 269 (M⁺, 5), 240 (14), 198 (9), 184 (22), 170 (100), 156 (44), 144 (30), 143 (25), 131 (22), 130 (26), 129 (22), 128 (21), 115 (32), 89 (16), 77 (7), 63 (7), 51 (7), 43 (22), 41 (51%).

3.3.2. 3-Cyclohexyl-8H-[1,2,3]triazolo[5,1-a]isoindole (6b). Compound **6b** was prepared from **4b** (0.150 g. 0.47 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.107 g of compound **6b** (95% yield). After crystallization from ethyl acetate/ petroleum ether, compound **6b** was obtained as a pale brown solid, mp=124-125 °C. [Found: C, 75.30; H, 7.20; N, 17.63. C₁₅H₁₇N₃ requires C, 75.28; H, 7.16; N, 17.56%.] v_{max} (KBr) 3072, 2919, 2849, 1448, 1421, 1340, 1258, 1156, 994, 773, 754, 729; $\delta_{\rm H}$ (400 MHz, CD₂Cl₂) 7.69 (d, J=8.0 Hz, 1H), 7.53–7.43 (m, 2H), 7.38 (td, J=7.6, 1.2 Hz, 1H), 5.27 (s, 2H), 3.00 (tt, J=12.0, 3.6 Hz, 1H), 2.08–2.00 (m, 2H), 1.94–1.85 (m, 2H), 1.84–1.65 (m, 3H), 1.55–1.31 (m, 3H); δ_c (100.6 MHz, CD₂Cl₂) 144.4, 141.1, 138.5, 128.7, 128.6, 127.5, 124.2, 121.4, 50.9, 36.3, 32.8, 26.5, 26.1; MS m/z 239 (M⁺, 8), 210 (64), 196 (15), 182 (100), 168 (36), 156 (13), 144 (15), 130 (22), 117 (15), 115 (13), 89 (19), 77 (19), 63 (14), 51 (15), 41 (33%).

3.3.3. 3-(Cyclopentylmethyl)-8H-[1,2,3]triazolo[5,1-a]isoindole (6c). Compound 6c was prepared from 4c (0.150 g, 0.47 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.098 g of compound 6c (87% yield). After crystallization from ethyl acetate/petroleum ether, compound 6c was obtained as a pale brown solid, mp=104-105 °C. [Found: C, 75.32; H, 7.21; N, 17.60. C₁₅H₁₇N₃ requires C, 75.28; H, 7.16; N, 17.56%.] ν_{max} (KBr) 2941, 2919, 2855, 1447, 1261, 1169, 1093, 1025, 798, 771, 744, 722; δ_H (400 MHz, CDCl₃) 7.59 (br d, J=7.6 Hz, 1H), 7.50–7.41 (m, 2H), 7.35 (td, J=7.6, 1.2 Hz, 1H), 5.28 (s, 2H), 2.92 (d, J=7.6 Hz, 2H), 2.35 (septet, J=7.6 Hz, 1H), 1.82-1.72 (m, 2H), 1.70-1.59 (m, 2H), 1.58-1.48 (m, 2H), 1.36–1.22 (m, 2H); δ_C (100.6 MHz, CDCl₃) 140.7, 139.5, 138.8, 128.7, 128.6, 127.6, 124.1, 120.8, 50.9, 40.5, 32.3, 31.7, 25.0; MS m/z 239 (M⁺, 17), 210 (58), 196 (13), 182 (81), 168 (63), 144 (25), 143 (34), 142 (42), 130 (49), 115 (56), 89 (33), 77 (15), 63 (19) 51 (18), 41 (100%).

3.3.4. 3-Phenyl-8H-[1,2,3]triazolo[5,1-a]isoindole (**6d**)¹¹. Compound **6d** was prepared from **4d** (0.152 g, 0.42 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.067 g of compound **6d** (68% yield). After crystallization from ethyl acetate/petroleum ether, compound **6d** was obtained as a pale brown solid, mp=153–155 °C. [Found: C, 77.30; H, 4.80; N, 17.93. C₁₅H₁₁N₃

requires C, 77.23; H, 4.75; N, 18.01%.] ν_{max} (KBr) 3058, 3034, 2964, 2922, 2850, 1609, 1448, 1359, 985, 760, 699, 668; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.95–7.90 (m, 2H), 7.88 (br d, *J*=7.2 Hz, 1H), 7.54–7.37 (m, 6H), 5.35 (s, 2H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 141.1, 139.3, 139.0, 131.2, 128.9, 128.8, 128.4, 128.1, 128.1, 126.9, 124.2, 121.3, 50.9; MS *m*/*z* 233 (M⁺, 7), 205 (54), 204 (100), 190 (14), 176 (20), 151 (11), 102 (68), 89 (39), 88 (39), 76 (44), 63 (25), 51 (25), 50 (19%).

3.3.5. 3-(4-Methylphenyl)-8H-[1,2,3]triazolo[5,1-a]isoindole (**6e**). Compound 6e was prepared from 4e (0.148 g, 0.45 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.098 g of compound **6e** (87% yield). After crystallization from ethyl acetate/petroleum ether, compound 6e was obtained as a white solid, mp=160–162 °C. [Found: C, 77.80; H, 5.35; N, 17.03. C₁₆H₁₃N₃ requires C, 77.71; H, 5.30; N, 16.99%.] v_{max} (KBr) 3067, 3024, 2963, 2918, 2853, 1437, 1413, 1354, 1176, 1128, 984, 829, 810, 764, 714; $\delta_{\rm H}$ (400 MHz, acetone- d_6) 7.95 (d, J=7.2 Hz, 1H), 7.88-7.83 (m, 2H), 7.72-7.68 (m, 1H), 7.55-7.49 (m, 1H), 7.47 (td, J=7.6, 1.2 Hz, 1H), 7.39–7.34 (m, 2H), 5.50 (s, 2H), 2.40 (s, 3H); δ_{C} (100.6 MHz, acetone-d₆) 144.1, 140.4, 140.2, 139.5, 131.4, 130.9, 130.4, 130.1, 129.9, 128.5, 126.5, 122.8, 52.6, 22.3; MS m/z 247 (M⁺, 14), 219 (89), 218 (100), 204 (88), 203 (38), 189 (18), 176 (15), 166 (10), 116 (10), 109 (39), 102 (37), 95 (42), 94 (33), 89 (21), 82 (46), 76 (26), 63 (26), 51 (30), 50 (22%).

3.3.6. 3-(4-*Methoxyphenyl*)-8*H*-[1,2,3]*triazolo*[5,1-*a*]*isoindole* (**6***f*). Compound **6***f* was prepared from **4***f* (0.149 g, 0.38 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% petroleum ether/ethyl acetate) afforded 0.098 g of compound **6***f* (98% yield). After crystallization from ethyl acetate/petroleum ether, compound **6***f* was obtained as a white solid, mp=154–156 °C. [Found: C, 72.85; H, 5.02; N, 16.03. C₁₆H₁₃N₃O requires C, 72.99; H, 4.98; N, 15.96%.] ν_{max} (KBr) 3064, 2961, 2922, 2850, 1615, 1508, 1454, 1420, 1356, 1298, 1246, 1174, 1100, 1031, 825, 803, 768; $\delta_{\rm H}$ (400 MHz, acetone-*d*₆) 7.93–7.86 (m, 3H), 7.69–7.65 (m, 1H), 7.52–7.47 (m, 1H), 7.44 (td, *J*=7.6, 1.2 Hz, 1H), 7.13–7.07 (m, 2H), 5.47 (s, 2H), 3.87 (s, 3H); $\delta_{\rm C}$ (100.6 MHz, acetone-*d*₆) 161.5, 144.0, 140.2, 139.8, 130.3, 130.0, 129.9, 129.9, 126.4, 126.1, 122.6, 116.2, 56.6, 52.6.

3.3.7. 3-(Thiophen-3-yl)-8H-[1,2,3]triazolo[5,1-a]isoindole (6g). Compound **6g** was prepared from **4g** (0.150 g, 0.47 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% ethyl acetate/petroleum ether) afforded 0.107 g of compound 6g (95% yield). After crystallization from ethyl acetate/ petroleum ether, compound 6g was obtained as a green solid, mp=178-180 °C. [Found: C, 65.32; H, 3.85; N, 17.60; S, 13.35. C₁₃H₉N₃S requires C, 65.25; H, 3.79; N, 17.56; S, 13.40%.] v_{max} (KBr) 3101, 2963, 2924, 2848, 1420, 1402, 1319, 1171, 1121, 1070, 867, 856, 793, 773, 730, 708; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.85 (br d, *I*=7.6 Hz, 1H), 7.74 (dd, J=2.8, 1.2 Hz, 1H), 7.64 (dd, J=4.8, 1.2 Hz, 1H) 7.53-7.49 (m, 1H), 7.49–7.43 (m, 2H), 7.40 (td, J=7.6, 1.2 Hz, 1H), 5.33 (s, 2H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 140.9, 138.4, 135.0, 132.0, 128.7, 128.2, 127.8, 126.5, 126.3, 124.1, 122.0, 121.0, 50.9; MS m/z 239 (M⁺, 12), 211 (99), 210 (100), 184 (27), 166 (19), 152 (10), 139 (29), 105 (14), 102 (17), 92 (61), 79 (22), 63 (25), 51 (22), 45 (60%).

3.3.8. 1-Pentyl-5,6-dihydro[1,2,3]triazolo[5,1-a]isoquinoline (7a). Compound 7a was prepared from 5a (0.173 g, 0.47 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.107 g of compound 7a (94% yield) as a pale yellow oil. [Found: C, 74.67; H, 7.87; N, 17.50. $C_{15}H_{19}N_3$ requires C, 74.65; H, 7.94; N, 17.41%.] v_{max} (neat) 2953, 2923, 2857, 1476, 1466, 1456, 1373, 1351, 1338, 1306, 1196, 768, 740, 731, 682; δ_{H} (400 MHz, CDCl₃) 7.58 (d, J=7.6, 1H), 7.38–7.25 (m, 3H), 4.52 (t, J=6.8 Hz, 2H), 3.17 (t, J=6.8 Hz, 2H), 2.94 (t, J=7.6 Hz, 2H), 1.78 (quintet, J=7.6 Hz, 2H), 1.46–1.30 (m, 4H), 0.88 (t, J=7.0 Hz, 3H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 143.5, 132.4, 128.8, 128.5, 128.4, 127.7, 125.6, 124.0, 44.7, 31.7, 29.3, 28.6, 26.5, 22.4, 14.0; MS *m*/*z* 241 (M⁺, 16), 212 (23), 198 (25), 185 (100), 184 (59), 170 (47), 156 (45), 143 (20), 130 (35), 129 (48), 128 (53), 127 (21), 115 (57), 103 (20), 91 (10), 89 (10), 77 (34), 63 (12), 51 (23), 41 (41%).

3.3.9. *1*-Octyl-5,6-dihydro[1,2,3]triazolo[5,1-a]isoquinoline (**7b**). Compound **7b** was prepared from **5b** (0.189 g, 0.46 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.118 g of compound **7b** (91% yield) as a pale yellow oil. [Found: C, 76.27; H, 8.87; N, 17.50. C₁₈H₂₅N₃ requires C, 76.28; H, 8.89; N, 17.63%.] ν_{max} (neat) 2923, 2854, 1476, 1466, 1439, 1371, 1190, 767, 739, 729, 682; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.57 (d, *J*=7.6, 1H), 7.37–7.24 (m, 3H), 4.51 (t, *J*=6.8 Hz, 2H), 3.16 (t, *J*=6.8 Hz, 2H), 2.93 (t, *J*=8.0 Hz, 2H), 1.76 (quintet, *J*=8.0 Hz, 2H), 1.47–1.37 (m, 2H), 1.36–1.16 (m, 8H), 0.84 (t, *J*=7.0 Hz, 3H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 143.4, 132.4, 128.8, 128.5, 128.4, 127.7, 125.6, 124.0, 44.7, 31.8, 29.4, 29.3, 29.2, 29.1, 28.9, 26.5, 22.6, 14.0; MS *m*/z 283 (M⁺, 14), 254 (18), 240 (10), 212 (10), 198 (39), 185 (100), 184 (60), 170 (42), 156 (35), 143 (16), 130 (27), 129 (29), 128 (33), 115 (35), 103 (14), 77 (14), 55 (8), 51 (8), 41 (39%).

3.3.10. 1-Cyclohexyl-5,6-dihydro[1,2,3]triazolo[5,1-a]isoquinoline (7c). Compound 7c was prepared from 5c (0.130 g, 0.39 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.086 g of compound **7c** (87% yield). After crystallization from ethyl acetate/petroleum ether, compound 7c was obtained as a white solid, mp=84-86 °C. [Found: C, 75.90; H, 7.63; N, 16.65. C₁₆H₁₉N₃ requires C, 75.85; H, 7.56; N, 16.59%.] ν_{max} (KBr) 3060, 2927, 2850, 1474, 1443, 1338, 1190, 993, 778, 756, 730, 684; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.56 (d, J=7.6 Hz, 1H), 7.34 (td, J=7.6, 2.0 Hz, 1H), 7.31–7.23 (m, 2H), 4.49 (t, J=6.8 Hz, 2H), 3.14 (t, J=6.8 Hz, 2H), 3.01–2.91 (m, 1H), 2.02–1.92 (m, 2H), 1.91–1.70 (m, 5H), 1.48–1.26 (m, 3H); δ_{C} (100.6 MHz, CDCl₃) 147.9, 132.6, 128.4, 128.3, 127.9, 127.7, 125.7, 124.1, 44.6, 35.9, 32.2, 29.3, 26.6, 25.9; MS m/z 253 (M⁺, 36), 224 (100), 196 (83), 185 (49), 182 (72), 168 (26), 167 (28), 141 (15), 130 (21), 128 (25), 115 (44), 103 (20), 91 (24), 84 (18), 77 (41), 63 (13), 55 (16), 51 (23), 41 (55%).

3.3.11. 1-Phenyl-5,6-dihydro[1,2,3]triazolo[5,1-a]isoquinoline (7d). Compound 7d was prepared from 5d (0.139 g, 0.37 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.075 g of compound **7d** (82% yield). After crystallization from ethyl acetate/petroleum ether, compound 7d was obtained as a yellow solid, mp=154-156 °C. [Found: C, 77.80; H, 5.35; N, 16.95. C₁₆H₁₃N₃ requires C, 77.71; H, 5.30; N, 16.99%.] *v*_{max} (KBr) 3057, 3044, 3032, 2972, 2947, 2913, 1478, 1466, 1448, 1365, 1340, 1232, 1191, 1152, 987, 784, 764, 750, 730, 705, 682; $\delta_{\rm H}$ (400 MHz, acetone- d_6) 7.72–7.67 (m, 2H), 7.56–7.53 (m, 1H), 7.52–7.41 (m, 4H), 7.33 (td, *J*=7.6, 1.2 Hz, 1H), 7.25–7.19 (m, 1H), 4.60 (t, J=6.8 Hz, 2H), 3.32 (t, J=6.8 Hz, 2H); $\delta_{\rm C}$ (100.6 MHz, acetone- d_6) 144.2, 135.6, 134.3, 130.9, 130.8, 130.6, 130.5, 130.2, 130.1, 129.0, 127.0, 125.8, 46.6, 30.8; MS m/z 247 (M⁺, 14), 219 (31), 218 (24), 204 (23), 189 (12), 165 (7), 141 (8), 116 (80), 115 (100), 109 (36), 96 (29), 94 (30), 82 (32), 63 (14), 51 (18%).

3.3.12. 1-(4-Methylphenyl)-5,6-dihydro[1,2,3]triazolo [5,1-a]isoquinoline (**7e**). Compound **7e** was prepared from **5e** (0.167 g, 0.43 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.093 g of compound **7e** (83% yield). After crystallization from ethyl acetate/petroleum ether, compound **7e** was obtained as a yellow solid, mp=140–142 °C. [Found: C, 78.20; H, 5.75; N, 16.05. C₁₇H₁₅N₃ requires C, 78.13; H, 5.79; N, 16.08%.] ν_{max} (KBr) 3055, 3016, 2943, 2914, 1514, 1469, 1366, 1349, 1342, 1184, 991, 827, 773, 748, 738, 556; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.61–7.57 (m, 3H), 7.32–7.22 (m, 4H), 7.16 (td, *J*=7.6, 1.2 Hz, 1H), 4.55 (t, *J*=6.8 Hz, 2H) 3.22 (t, *J*=6.8 Hz, 2H), 2.40 (s, 3H); $\delta_{\rm C}$ (100.6 MHz, CDCl₃) 143.0, 138.2, 132.7, 129.3, 129.0, 128.9, 128.7, 128.4, 128.3, 127.4, 125.1, 124.3, 44.9, 29.2, 21.3; MS *m/z* 261 (M⁺, 10), 233 (27), 218 (15), 203 (15), 189 (8), 141 (12), 116 (79), 115 (100), 109 (21), 103 (15), 102 (18), 101 (16), 94 (11), 89 (23), 77 (10), 76 (12), 63 (10), 51 (13%).

3.3.13. 1-(4-Methoxyphenyl)-5,6-dihydro[1,2,3]triazolo [5,1-a]isoquinoline (7f). Compound 7f was prepared from 5f (0.150 g, 0.42 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 40% petroleum ether/ethyl acetate) afforded 0.086 g of compound **7f** (74% yield). After crystallization from ethyl acetate/petroleum ether, compound **7f** was obtained as a pale yellow solid, mp=116-117 °C. [Found: C, 73.68; H, 5.49; N, 15.09. C₁₇H₁₅N₃O requires C, 73.63; H, 5.45; N, 15.15%.] v_{max} (KBr) 3067, 2956, 2923, 2838, 1610, 1508, 1466, 1458, 1366, 1297, 1246, 1228, 1190, 1178, 1023, 843, 769; δ_H (400 MHz, CDCl₃) 7.62–7.57 (m, 2H), 7.56–7.53 (m, 1H), 7.30–7.26 (m, 1H), 7.23 (td, *J*=7.6, 1.2 Hz, 1H), 7.14 (td, *J*=7.6, 1.2 Hz, 1H), 6.98–6.93 (m, 2H), 4.53 (t, *J*=6.8 Hz, 2H), 3.82 (s, 3H), 3.20 (t, *J*=6.8 Hz, 2H); δ_C(100.6 MHz, CDCl₃) 159.6, 142.7, 132.7, 129.7, 128.8, 128.7, 128.4, 127.3, 125.1, 124.1, 123.9, 114.0, 55.2, 44.9, 29.2; MS m/z 277 (M⁺, 14), 249 (32), 234 (30), 219 (7), 218 (7), 206 (9), 204 (9), 178 (14), 152 (9), 141 (13), 116 (77), 115 (100), 111 (20), 103 (11), 102 (18), 94 (12), 89 (19), 88 (14), 82 (10), 76 (23), 63 (16), 51 (14%).

3.3.14. 1-(Thiophen-3-vl)-5.6-dihvdro[1.2.3]triazolo [5.1-alisoauino*line* (**7g**). Compound **7g** was prepared from **5g** (0.130 g, 0.34 mmol) in accordance with general procedure. Purification by column chromatography (silica gel, 50% ethyl acetate/petroleum ether) afforded 0.075 g of compound 7g (87% yield). After crystallization from ethyl acetate/petroleum ether, compound 7g was obtained as a yellow solid, mp=160-162 °C. [Found: C, 66.32; H, 4.42; N, 16.60; S, 12.72. C₁₄H₁₁N₃S requires C, 66.38; H, 4.38; N, 16.59; S, 12.66%.] v_{max} (KBr) 3095, 3073, 2929, 1484, 1474, 1466, 1458, 1400, 1348, 1321, 1288, 1240, 1184, 1133, 857, 802, 774, 743, 640; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.68-7.64 (m, 2H), 7.42-7.39 (m, 2H), 7.33-7.30 (m, 1H), 7.28 (td, J=7.6, 1.2 Hz, 1H), 7.21 (td, J=7.6, 1.6 Hz, 1H), 4.55 (t, J=6.8 Hz, 2H), 3.22 (t, *J*=6.8 Hz, 2H); δ_C (100.6 MHz, CDCl₃) 138.6, 132.8, 132.1, 129.2, 129.1, 128.5, 127.6, 127.5, 126.0, 125.0, 124.3, 123.8, 44.9, 29.2; MS m/z 253 (M⁺, 16), 225 (38), 224 (20), 210 (17), 197 (8), 191 (6), 165 (8), 152 (11), 141 (10), 116 (77), 115 (100), 112 (16), 98 (38), 89 (11), 85 (11), 77 (12), 76 (11), 63 (13), 51 (15), 45 (36%).

Acknowledgements

This work was financially supported by the University of Bari (Italy).

References and notes

- (a) Lee, T.; Cho, M.; Ko, S.-Y.; Youn, H.-J.; Baek, D. J.; Cho, W.-J.; Kang, C.-Y.; Kim, S. J. Med. Chem. 2007, 50, 585–589; (b) Xia, Y.; Fan, Z.; Yao, J.; Liao, Q.; Li, W.; Qu, F.; Peng, L. Bioorg. Med. Chem. Lett. 2006, 16, 2693–2698.
- (a) Fournier, D.; Hoogenboom, R.; Schubert, U. S. Chem. Soc. Rev. 2007, 36, 1369–1380; (b) Nandivada, H.; Jiang, X.; Lahann, J. Adv. Mater. 2007, 19, 2197–2208; (c) Angell, Y. L; Burgess, K. Chem. Soc. Rev. 2007, 36, 1369–1380; (d) Moses, J. E.; Moorhouse, A. D. Chem. Soc. Rev. 2007, 36, 1249–1262; (e) Lutz, J.-F. Angew. Chem., Int. Ed. 2007, 46, 1018–1025.

- Genin, M. J.; Allwine, D. A.; Anderson, D. J.; Barbachyn, M. R.; Emmert, D. E.; Garmon, S. A.; Graber, D. R.; Grega, K. C.; Hester, J. B.; Hutchinson, D. K.; Morris, J.; Reischer, R. J.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H. J. Med. Chem. 2000, 43, 953–970.
- (a) Buckle, D. R.; Rockell, C. J. M.; Smith, H.; Spicer, B. A. J. Med. Chem. 1986, 29, 2262–2267; (b) Buckle, D. R.; Outred, D. J.; Rockell, C. J. M.; Smith, H.; Spicer, B. A. J. Med. Chem. 1983, 26, 251–254.
- Giffin, M. J.; Heaslet, H.; Brik, A.; Lin, Y.-C.; Cauvi, G.; Wong, C.-H.; McRee, D. E.; Elder, J. H.; Stout, C. D.; Torbett, B. E. J. Med. Chem. 2008, 51, 6263–6270.
- (a) Huisgen, R. *Pure Appl. Chem.* **1989**, *61*, 613–628; (b) Huisgen, R. In *1,3-Dipolar Cycloaddition Chemistry*; Padwa, A., Ed.; Wiley: New York, NY, 1984; pp 1–176.
- Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596–2599.
- 8. Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057-3064.
- Selected reviewes: (a) Amblard, F.; Cho, J. H.; Schinazi, R. F. Chem. Rev. 2009, 109, 4207–4220; (b) Meldal, M.; Tornøe, C. W. Chem. Rev. 2008, 108, 2952–3015; Gil, M. V.; Arévalo, M. J.; López, Ó. Synthesis 2007, 1589–1620.
- (a) James, D.; Escudier, J.-M.; Amigues, E.; Schulz, J.; Vitry, C.; Bordenave, T.; Slozek-Pinaud, M.; Fouquet, E. *Tetrahedron Lett.* **2010**, *51*, 1230–1232; (b) 10 Montagnat, O. D.; Lessene, G.; Hughes, A. B. J. Org. Chem. 2010, 75, 390-398; (c) Cravotto, G.; Fokin, V. V.; Garella, D.; Binello, A.; Boffa, L.; Barge, A. J. Comb. Chem. 2010, 12, 13-15; (d) Jurícek, M.; Kouwer, P. H. J.; Rehák, J.; Sly, J.; Rowan, A. E. J. Org. Chem. 2009, 74, 21-25; (e) Xia, Y.; Liu, Y.; Wan, J.; Wang, M.; Rocchi, P.; Qu, F.; Iovanna, J. L.; Peng, L. J. Med. Chem. 2009, 52, 6083-6096; (f) Broggi, J.; Díez-González, S.; Petersen, J. L.; Berteina-Raboin, S.; Nolan, S. P.; Agrofoglio, L. A. Synthesis 2008, 141-148; (g) Li, P.; Wang, L.; Zhang, Y. Tetrahedron 2008, 64, 10825-10830; (h) Jlalia, I.; Elamari, H.; Meganem, F.; Herscovici, J.; Girard, C. Tetrahedron Lett. 2008, 49, 6756-6758; (i) Wang, Z.-X.; Zhao, Z.-G. J. Heterocycl. Chem. 2007, 44, 89-92; (j) Chassaing, S.; Kumarraja, M.; Sido, A. S. S.; Pale, P.; Sommer, J. Org. Lett. 2007, 9, 883–886; (k) Yoo, E. J.; Ahlquist, M.; Kim, S. H.; Bae, I.; Fokin, V. V.; Sharpless, K. B.; Chang, S. Angew. Chem., Int. Ed. 2007, 46, 1730-1733; (1) Bertrand, P.; Gesson, J. P. J. Org. Chem. 2007, 72, 3596-3599.
- (a) Brawn, R. A.; Welzel, M.; Lowe, J. T.; Panek, J. S. Org. Lett. 2010, 336–339; (b) Majumdar, K. C.; Ray, K.; Ganai, S.; Ghosh, T. Synthesis 2010, 858–862; (c) Hu, Y.-Y.; Hu, J.; Wang, X.-C.; Guo, L.-N.; Shu, X.-Z.; Niu, Y.-N.; Liang, Y.-M. Tetrahedron 2010, 66, 80–86; (d) Chowdhury, C.; Mukherjee, S.; Das, B.; Achari, B. J. Org. Chem. 2009, 74, 3612–3615; (e) Chowdhury, C.; Sasmal, A. K.; Dutta, P. K. Tetrahedron Lett. 2009, 50, 2678–2681; (f) Mohapatra, D. K.; Maity, P. K.; Shabab, M.; Khan, M. I. Bioorg. Med. Chem. Lett. 2009, 19, 5241–5245; (g) Laleu, B.; Lautens, M.J. Org. Chem. 2008, 73, 9164–9167; (h) Chen, W. L.; Su, C. L.; Huang, X. Synlett 2006, 1446–1448; (i) Dolhem, F.; Thali, F. A.; Lièvre, C.; Demailly, G. Eur. J. Org. Chem. 2005, 5019–5023; (l) Chowdhury, C.; Mandal, S. B.; Achari, B. Tetrahedron Lett. 2005, 46, 8531–8534.
- Shafran, E. A.; Bakulev, V. A.; Rozin, Y. A.; Shafran, Y. M. Chem. Heterocycl. Comp. 2008, 44, 1040–1069.
- Selected reviewes: (a) Jazzar, R.; Hitce, J.; Renaudat, A.; Sofack-Kreutzer, J.; Baudoin, O. Chem.—Eur, J. 2010, 16, 2654–2672; (b) Ackermann, L.; Vicente, R.; Kapdi, A. R. Angew. Chem., Int. Ed. 2009, 48, 9792–9826; (c) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094–5115; (d) Daugulis, O.; Do, H.-Q.; Shabashov, D. Acc. Chem. Res. 2009, 42, 1074–1086.
- (a) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2008, 64, 53–60; (b) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2008, 64, 7301–7306; (c) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2006, 62, 5126–5132; (d) Fiandanese, V.; Bottalico, D.; Cardellicchio, C.; Marchese, G.; Punzi, A. Tetrahedron 2005, 61, 4551–4556; (e) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2005, 3004–3008; (f) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2005, 60, 3004–3008; (f) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A. Tetrahedron 2006, 60, 11421–11425.
- (a) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A.; Quarta, M. R.; Fittipaldi, M. Synthesis 2009, 3853–3859; (b) Fiandanese, V.; Bottalico, D.; Marchese, G.; Punzi, A.; Capuzzolo, F. Tetrahedron 2009, 65, 10573–10580.
- For a comprehensive review, see: Fiandanese, V.; Bottalico, D. Curr. Org. Chem. 2009, 13, 554–572.
- Chuprakov, S.; Chernyak, N.; Dudnik, A. S.; Gevorgyan, V. Org. Lett. 2007, 9, 2333–2336.
- Bentley, K. W. The Isoquinoline Alkaloids; Hardwood Academic: Amsterdam, The Netherlands, 1998; Vol. 1.
- (a) Kletsas, D.; Li, W.; Han, Z.; Papadopoulos, V. Biochem. Pharmacol. 2004, 67, 1927–1932; (b) Mach, U. R.; Hackling, A. E.; Perachon, S.; Ferry, S.; Wermuth, C. G.; Schwartz, J.-C.; Sokoloff, P.; Stark, H. ChemBioChem 2004, 5, 508–518; (c) Muscarella, D. E.; O'Brain, K. A.; Lemley, A. T.; Bloom, S. E. Toxicol. Sci. 2003, 74, 66–73; (d) Dzierszinski, F.; Coppin, A.; Mortuaire, M.; Dewally, E.; Slomianny, C.; Ameisen, J.-C.; DeBels, F.; Tomavo, S. Antimicrob. Agents Chemother. 2002, 46, 3197–3207.